

**PRESS RELEASE****Noida, Tuesday, August 05, 2014**

## **JUBILANT LIFE SCIENCES**

---

The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company met today to approve financial results for the quarter ended June 30, 2014.

**Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:**

“Performance of the quarter was affected due to extended plant shut-down in CMO business to address USFDA issues. These operations have now normalized and, along with new product introductions and strategic initiatives, should deliver strong performance in our Pharmaceutical operations. In Life Science Ingredients, we witnessed growth across all businesses aided by price and volume gains. We are confident that we have laid the foundation for a strong performance in the remaining quarters of the year.”

### **Q1 FY2015 Highlights**

- Consolidated revenue at Rs. 1,473 Crore, grew 8% YoY
- International revenues at Rs. 1,051 crore, contributed 71% to the overall mix
- EBITDA margins at 10.2% and Reported PAT at 5 Crore

### **Corporate Actions**

We have completed the consolidation of all our Pharmaceutical business under Jubilant Pharma, Singapore with effect from 1st July, 2014. This has been financed by a US\$ 147.5m funding from IFC, which includes US\$ 87.5m long term loan, US\$ 60m of zero coupon optionally convertible loan and a further loan of US\$ 52.5m to be syndicated by IFC.

### **Pharmaceuticals Segment Review**

In Q1 FY2015, Income from operations of the Pharmaceuticals segment stood at Rs. 604 crore, contributing 41% to the revenue mix. The segment EBITDA stood at Rs. 36 crore with EBITDA margins of 5.9%.

### **Life Science Ingredients Segment Review**

In Q1 FY2015, Income from operations for the Life Science Ingredients segment stood at Rs. 869 crore, growing 23% YoY and contributing 59% to total revenues. The segment EBITDA was at Rs. 133 crore with EBITDA margins at 15.3%.



## Geographical Overview

International revenues contributed 71% to the revenue mix at Rs. 1,051 crore, with regulated markets contributing 56% to the revenue mix in Q1 FY2015. Revenues from North America stood at Rs. 490 crore, contributing 33% to the overall revenues and revenues from Europe and Japan stood at Rs. 330 crore, thus contributing 22% to the revenue mix. Domestic revenues were up 18% YoY at Rs. 422 crore, contributing 29% to the revenue mix. Revenues in ROW including China stood at Rs. 230 crore, up 12% YoY and contributing 16% to the revenue mix.

## Outlook

We expect strong growth momentum in our coming quarters, led by our Pharmaceuticals segment. This growth in Pharmaceuticals will be driven by new products and new markets, expanding volumes in CMO operations and revenue increase in Radiopharmaceuticals. Life Science Ingredients should continue its robust performance on account of higher capacity utilization, better pricing of our key products and expansion into new markets.

## About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com)

## For more information please contact:

### *For Investors*

Ravi Agrawal  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)

Siddharth Rangnekar  
CDR India  
Ph: +91 22 6645 1209  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1021  
E-mail: [anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Karl Kolah  
CDR India  
Ph: +91 22 6645 1220  
E-mail: [karl@cdr-india.com](mailto:karl@cdr-india.com)



**For Media**

Neha Garg  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1067  
E-mail: neha\_garg@jubl.com

Kanika Mittal  
Perfect Relations  
Ph: +91 9899574833  
E-mail: kmittal@perfectrelations.com

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*